Project Details
Targeting immunosuppressive programs in isocitrate dehydrogenase mutant gliomas (B03)
Subject Area
Hematology, Oncology
Term
since 2019
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 404521405
This project aims at evaluating and targeting immuno-relevant glioma cell-intrinsic and -extrinsic factors and microenvironmental immunomodulation to develop combinatorial targeted (immuno-) therapies for isocitrate dehydrogenase (IDH) mutant gliomas. The strategic aim is to utilize immuno-relevant IDH-associated as well as tertiary and quaternary genetic event-associated vulnerabilities in pathophysiologically optimized preclinical glioma models for rationalizing combinatorial clinical trials.
DFG Programme
Collaborative Research Centres
Applicant Institution
Ruprecht-Karls-Universität Heidelberg
Project Heads
Dr. Lukas Bunse, since 7/2019; Privatdozent Dr. Stefan Pusch